Gastrointestinal microbiota-directed nutritional and therapeutic interventions for inflammatory bowel disease: opportunities and challenges
Abstract Evidence-based research has confirmed the role of gastrointestinal microbiota in regulating intestinal inflammation. These data have generated interest in developing microbiota-based therapies for the prevention and management of inflammatory bowel disease (IBD). Despite in-depth understand...
Gespeichert in:
| Veröffentlicht in: | Gastroenterology report 2024, Vol.12, p.goae033 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | goae033 |
| container_title | Gastroenterology report |
| container_volume | 12 |
| creator | Paudel, Devendra Nair, Divek V T Joseph, Grace Castro, Rita Tiwari, Amit K Singh, Vishal |
| description | Abstract
Evidence-based research has confirmed the role of gastrointestinal microbiota in regulating intestinal inflammation. These data have generated interest in developing microbiota-based therapies for the prevention and management of inflammatory bowel disease (IBD). Despite in-depth understanding of the etiology of IBD, it currently lacks a cure and requires ongoing management. Accumulating data suggest that an aberrant gastrointestinal microbiome, often referred to as dysbiosis, is a significant environmental instigator of IBD. Novel microbiome-targeted interventions including prebiotics, probiotics, fecal microbiota transplant, and small molecule microbiome modulators are being evaluated as therapeutic interventions to attenuate intestinal inflammation by restoring a healthy microbiota composition and function. In this review, the effectiveness and challenges of microbiome-centered interventions that have the potential to alleviate intestinal inflammation and improve clinical outcomes of IBD are explored. |
| doi_str_mv | 10.1093/gastro/goae033 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11057942</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/gastro/goae033</oup_id><sourcerecordid>3049716632</sourcerecordid><originalsourceid>FETCH-LOGICAL-c425t-46bc72628cea1bc7a90d8260f35abeadde86607aa1be514a3906a698a62e4f0d3</originalsourceid><addsrcrecordid>eNqFkUFv1DAQhS0EolXplSPKEQ5px3biJFwQqqAgVeICZ2sST3aNnDjYTqv-Bv40TnepyomTR35vvhnNY-w1hwsOnbzcYUzBX-48Ekj5jJ0KqEUJIKvnT-oTdh7jTwDg0Iia1y_ZiWxVB6KDU_b7-oFh50Qx2RldMdkh-N76hKWxgYZEppjXFGyyftNxNkXaU8CF1mSHYmsNtzRvcixGH_LP6HCaMPlwX_T-jlxhbCSM9L7wy-JDWudMo_jAGvboHM07iq_YixFdpPPje8Z-fP70_epLefPt-uvVx5tyqESdykr1QyOUaAdCnkvswLRCwShr7AmNoVYpaDCLVPMKZQcKVdeiElSNYOQZ-3DgLms_kRny7gGdXoKdMNxrj1b_q8x2r3f-VnMOddNVIhPeHgnB_1rz5fRk40DO4Ux-jVpC1TVcKblZLw7WfNUYA42PczjoLUV9SFEfU8wNb55u92j_m1k2vDsY_Lr8D_YHEluvwg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3049716632</pqid></control><display><type>article</type><title>Gastrointestinal microbiota-directed nutritional and therapeutic interventions for inflammatory bowel disease: opportunities and challenges</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford Journals Open Access Collection</source><source>PubMed Central</source><creator>Paudel, Devendra ; Nair, Divek V T ; Joseph, Grace ; Castro, Rita ; Tiwari, Amit K ; Singh, Vishal</creator><creatorcontrib>Paudel, Devendra ; Nair, Divek V T ; Joseph, Grace ; Castro, Rita ; Tiwari, Amit K ; Singh, Vishal</creatorcontrib><description>Abstract
Evidence-based research has confirmed the role of gastrointestinal microbiota in regulating intestinal inflammation. These data have generated interest in developing microbiota-based therapies for the prevention and management of inflammatory bowel disease (IBD). Despite in-depth understanding of the etiology of IBD, it currently lacks a cure and requires ongoing management. Accumulating data suggest that an aberrant gastrointestinal microbiome, often referred to as dysbiosis, is a significant environmental instigator of IBD. Novel microbiome-targeted interventions including prebiotics, probiotics, fecal microbiota transplant, and small molecule microbiome modulators are being evaluated as therapeutic interventions to attenuate intestinal inflammation by restoring a healthy microbiota composition and function. In this review, the effectiveness and challenges of microbiome-centered interventions that have the potential to alleviate intestinal inflammation and improve clinical outcomes of IBD are explored.</description><identifier>ISSN: 2052-0034</identifier><identifier>EISSN: 2052-0034</identifier><identifier>DOI: 10.1093/gastro/goae033</identifier><identifier>PMID: 38690290</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Editor's Choice ; Review</subject><ispartof>Gastroenterology report, 2024, Vol.12, p.goae033</ispartof><rights>The Author(s) 2024. Published by Oxford University Press and Sixth Affiliated Hospital of Sun Yat-sen University 2024</rights><rights>The Author(s) 2024. Published by Oxford University Press and Sixth Affiliated Hospital of Sun Yat-sen University.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c425t-46bc72628cea1bc7a90d8260f35abeadde86607aa1be514a3906a698a62e4f0d3</citedby><cites>FETCH-LOGICAL-c425t-46bc72628cea1bc7a90d8260f35abeadde86607aa1be514a3906a698a62e4f0d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11057942/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11057942/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,1605,4025,27928,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38690290$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paudel, Devendra</creatorcontrib><creatorcontrib>Nair, Divek V T</creatorcontrib><creatorcontrib>Joseph, Grace</creatorcontrib><creatorcontrib>Castro, Rita</creatorcontrib><creatorcontrib>Tiwari, Amit K</creatorcontrib><creatorcontrib>Singh, Vishal</creatorcontrib><title>Gastrointestinal microbiota-directed nutritional and therapeutic interventions for inflammatory bowel disease: opportunities and challenges</title><title>Gastroenterology report</title><addtitle>Gastroenterol Rep (Oxf)</addtitle><description>Abstract
Evidence-based research has confirmed the role of gastrointestinal microbiota in regulating intestinal inflammation. These data have generated interest in developing microbiota-based therapies for the prevention and management of inflammatory bowel disease (IBD). Despite in-depth understanding of the etiology of IBD, it currently lacks a cure and requires ongoing management. Accumulating data suggest that an aberrant gastrointestinal microbiome, often referred to as dysbiosis, is a significant environmental instigator of IBD. Novel microbiome-targeted interventions including prebiotics, probiotics, fecal microbiota transplant, and small molecule microbiome modulators are being evaluated as therapeutic interventions to attenuate intestinal inflammation by restoring a healthy microbiota composition and function. In this review, the effectiveness and challenges of microbiome-centered interventions that have the potential to alleviate intestinal inflammation and improve clinical outcomes of IBD are explored.</description><subject>Editor's Choice</subject><subject>Review</subject><issn>2052-0034</issn><issn>2052-0034</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNqFkUFv1DAQhS0EolXplSPKEQ5px3biJFwQqqAgVeICZ2sST3aNnDjYTqv-Bv40TnepyomTR35vvhnNY-w1hwsOnbzcYUzBX-48Ekj5jJ0KqEUJIKvnT-oTdh7jTwDg0Iia1y_ZiWxVB6KDU_b7-oFh50Qx2RldMdkh-N76hKWxgYZEppjXFGyyftNxNkXaU8CF1mSHYmsNtzRvcixGH_LP6HCaMPlwX_T-jlxhbCSM9L7wy-JDWudMo_jAGvboHM07iq_YixFdpPPje8Z-fP70_epLefPt-uvVx5tyqESdykr1QyOUaAdCnkvswLRCwShr7AmNoVYpaDCLVPMKZQcKVdeiElSNYOQZ-3DgLms_kRny7gGdXoKdMNxrj1b_q8x2r3f-VnMOddNVIhPeHgnB_1rz5fRk40DO4Ux-jVpC1TVcKblZLw7WfNUYA42PczjoLUV9SFEfU8wNb55u92j_m1k2vDsY_Lr8D_YHEluvwg</recordid><startdate>2024</startdate><enddate>2024</enddate><creator>Paudel, Devendra</creator><creator>Nair, Divek V T</creator><creator>Joseph, Grace</creator><creator>Castro, Rita</creator><creator>Tiwari, Amit K</creator><creator>Singh, Vishal</creator><general>Oxford University Press</general><scope>TOX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2024</creationdate><title>Gastrointestinal microbiota-directed nutritional and therapeutic interventions for inflammatory bowel disease: opportunities and challenges</title><author>Paudel, Devendra ; Nair, Divek V T ; Joseph, Grace ; Castro, Rita ; Tiwari, Amit K ; Singh, Vishal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c425t-46bc72628cea1bc7a90d8260f35abeadde86607aa1be514a3906a698a62e4f0d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Editor's Choice</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paudel, Devendra</creatorcontrib><creatorcontrib>Nair, Divek V T</creatorcontrib><creatorcontrib>Joseph, Grace</creatorcontrib><creatorcontrib>Castro, Rita</creatorcontrib><creatorcontrib>Tiwari, Amit K</creatorcontrib><creatorcontrib>Singh, Vishal</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Gastroenterology report</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paudel, Devendra</au><au>Nair, Divek V T</au><au>Joseph, Grace</au><au>Castro, Rita</au><au>Tiwari, Amit K</au><au>Singh, Vishal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gastrointestinal microbiota-directed nutritional and therapeutic interventions for inflammatory bowel disease: opportunities and challenges</atitle><jtitle>Gastroenterology report</jtitle><addtitle>Gastroenterol Rep (Oxf)</addtitle><date>2024</date><risdate>2024</risdate><volume>12</volume><spage>goae033</spage><pages>goae033-</pages><issn>2052-0034</issn><eissn>2052-0034</eissn><abstract>Abstract
Evidence-based research has confirmed the role of gastrointestinal microbiota in regulating intestinal inflammation. These data have generated interest in developing microbiota-based therapies for the prevention and management of inflammatory bowel disease (IBD). Despite in-depth understanding of the etiology of IBD, it currently lacks a cure and requires ongoing management. Accumulating data suggest that an aberrant gastrointestinal microbiome, often referred to as dysbiosis, is a significant environmental instigator of IBD. Novel microbiome-targeted interventions including prebiotics, probiotics, fecal microbiota transplant, and small molecule microbiome modulators are being evaluated as therapeutic interventions to attenuate intestinal inflammation by restoring a healthy microbiota composition and function. In this review, the effectiveness and challenges of microbiome-centered interventions that have the potential to alleviate intestinal inflammation and improve clinical outcomes of IBD are explored.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>38690290</pmid><doi>10.1093/gastro/goae033</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2052-0034 |
| ispartof | Gastroenterology report, 2024, Vol.12, p.goae033 |
| issn | 2052-0034 2052-0034 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11057942 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford Journals Open Access Collection; PubMed Central |
| subjects | Editor's Choice Review |
| title | Gastrointestinal microbiota-directed nutritional and therapeutic interventions for inflammatory bowel disease: opportunities and challenges |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T03%3A04%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gastrointestinal%20microbiota-directed%20nutritional%20and%20therapeutic%20interventions%20for%20inflammatory%20bowel%20disease:%20opportunities%20and%20challenges&rft.jtitle=Gastroenterology%20report&rft.au=Paudel,%20Devendra&rft.date=2024&rft.volume=12&rft.spage=goae033&rft.pages=goae033-&rft.issn=2052-0034&rft.eissn=2052-0034&rft_id=info:doi/10.1093/gastro/goae033&rft_dat=%3Cproquest_pubme%3E3049716632%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3049716632&rft_id=info:pmid/38690290&rft_oup_id=10.1093/gastro/goae033&rfr_iscdi=true |